Jungwirth, G., Yu, T., Liu, F., Cao, J., Alaa Eddine, M., Moustafa, M., . . . Herold-Mende, C. (2023). Pharmacological landscape of FDA-approved anticancer drugs reveals sensitivities to ixabepilone, romidepsin, omacetaxine, and carfilzomib in aggressive meningiomas. Clinical cancer research, 29(1), . https://doi.org/10.1158/1078-0432.CCR-22-2085
Chicago-Zitierstil (17. Ausg.)Jungwirth, Gerhard, et al. "Pharmacological Landscape of FDA-approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas." Clinical Cancer Research 29, no. 1 (2023). https://doi.org/10.1158/1078-0432.CCR-22-2085.
MLA-Zitierstil (9. Ausg.)Jungwirth, Gerhard, et al. "Pharmacological Landscape of FDA-approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas." Clinical Cancer Research, vol. 29, no. 1, 2023, https://doi.org/10.1158/1078-0432.CCR-22-2085.